#HyBryte

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Soligenix to Showcase Major Developments at BIO Investment Summit in Miami Soligenix will present significant advancements in rare disease treatments during the BIO Investment & Growth Summit in Miami on March 2, 2026.

Soligenix to Showcase Major Developments at BIO Investment Summit in Miami #United_States #Miami_Beach #Soligenix #HyBryte #BIO_Summit

Thiard News@F4F

@newsen.bsky.social

1 month ago

Soligenix's 2026 Outlook: Progress, Innovations, and Future Prospects in Rare Disease Treatments Soligenix, Inc. shares its 2026 roadmap detailing significant clinical milestones in rare disease therapies and expected market opportunities.

Soligenix's 2026 Outlook: Progress, Innovations, and Future Prospects in Rare Disease Treatments #USA #Princeton #Soligenix #HyBryte #SGX945

Thiard News@F4F

@newsen.bsky.social

3 months ago

Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment Soligenix has successfully enrolled 50 patients in its HyBryte Phase 3 clinical trial for Cutaneous T-Cell Lymphoma, paving the way for a critical interim analysis in 2026.

Soligenix Reaches Key Enrollment Milestone in HyBryte Phase 3 Trial for Lymphoma Treatment #USA #Princeton #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

4 months ago

Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials Soligenix, Inc. outlines its recent milestones and third quarter financial results for 2025, focusing on clinical trials and future strategies.

Soligenix Reports Q3 2025 Financial Results and Major Developments in Clinical Trials #United_States #Princeton #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

5 months ago

Soligenix Announces Enhancements to Its Medical Advisory Board for HyBryte™ in Cutaneous T-Cell Lymphoma Soligenix has updated its Medical Advisory Board to enhance clinical strategies for HyBryte™, a promising therapy for cutaneous T-cell lymphoma, aiming for better patient outcomes.

Soligenix Announces Enhancements to Its Medical Advisory Board for HyBryte™ in Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #HyBryte #Cutaneous_T-Cell_Lymphoma

Thiard News@F4F

@newsen.bsky.social

5 months ago

Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma Soligenix has reached a significant safety milestone in their Phase 3 trial for HyBryte™, aimed at treating cutaneous T-cell lymphoma, confirming its acceptable safety profile.

Soligenix Reaches Major Safety Milestone for HyBryte™ in Treating Cutaneous T-Cell Lymphoma #United_States #Princeton #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

5 months ago

Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement Soligenix, Inc. has expanded its European Medical Advisory Board as they move forward with a Phase 3 clinical study for HyBryte™ in treating cutaneous T-cell lymphoma.

Soligenix Expands Medical Advisory Board for European CTCL Treatment Advancement #United_States #Princeton #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

5 months ago

Soligenix Welcomes Former White House Advisor Dr. Tomas J. Philipson as Strategic Consultant Soligenix has appointed Dr. Tomas J. Philipson, the former White House economic advisor, as a strategic consultant to guide its clinical and economic strategies.

Soligenix Welcomes Former White House Advisor Dr. Tomas J. Philipson as Strategic Consultant #USA #Princeton #Soligenix #HyBryte #Tomas_Philipson

Thiard News@F4F

@newsen.bsky.social

6 months ago

Soligenix's Participation in the H.C. Wainwright Annual Investment Conference to Showcase Innovations Soligenix, Inc. will present innovative therapies at the H.C. Wainwright 27th Annual Global Investment Conference, focusing on unmet medical needs.

Soligenix's Participation in the H.C. Wainwright Annual Investment Conference to Showcase Innovations #USA #Princeton #Biopharmaceutical #Soligenix #HyBryte

Thiard News@F4F

@newsen.bsky.social

7 months ago

Soligenix Reveals Q2 2025 Financial Report and Future Development Plans Soligenix, Inc. announces its second quarter 2025 financial results, affirming confidence in its late-stage biopharmaceutical projects addressing rare diseases.

Soligenix Reveals Q2 2025 Financial Report and Future Development Plans #USA #Princeton #Soligenix #HyBryte #SGX302

Thiard News@F4F

@newsen.bsky.social

7 months ago

Rare Diseases and Their Long-Term Revenue Potential: What Innovators Need to Know As the U.S. population ages, chronic and rare diseases become pressing health issues. Innovations in treatment signal a significant revenue opportunity for pharmaceutical companies.

Rare Diseases and Their Long-Term Revenue Potential: What Innovators Need to Know #United_States #New_York #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

8 months ago

Soligenix Unveils Promising Advances in Rare Disease Treatments and Future Plans Soligenix's latest corporate update outlines significant progress in clinical trials for treating rare diseases like CTCL and psoriasis. Key milestones expected.

Soligenix Unveils Promising Advances in Rare Disease Treatments and Future Plans #USA #Princeton #Soligenix #HyBryte #SGX302

Thiard News@F4F

@newsen.bsky.social

8 months ago

Soligenix Achieves Successful Transfer of Synthetic Hypericin Manufacturing to the U.S. Soligenix has transferred the manufacturing of synthetic hypericin to the U.S., paving the way for clinical trials and commercialization of treatments for CTCL and psoriasis.

Soligenix Achieves Successful Transfer of Synthetic Hypericin Manufacturing to the U.S. #United_States #Princeton #Soligenix #HyBryte #Synthetic_Hypericin

Thiard News@F4F

@newsen.bsky.social

10 months ago

Soligenix Provides Updates on Recent Achievements and Q1 2025 Financial Performance Soligenix, Inc. highlights its recent accomplishments and Q1 financial performance for 2025, showcasing advancements in clinical trials and research.

Soligenix Provides Updates on Recent Achievements and Q1 2025 Financial Performance #United_States #Princeton #Biopharmaceutical #Soligenix #HyBryte

Thiard News@F4F

@newsen.bsky.social

11 months ago

Promising Results from HyBryte™ Therapy Show 75% Success Rate in CTCL Patients Recent interim results reveal that 75% of patients with early-stage cutaneous T-cell lymphoma achieved treatment success using HyBryte™ within 18 weeks, showcasing its rapid action and safety.

Promising Results from HyBryte™ Therapy Show 75% Success Rate in CTCL Patients #United_States #Princeton #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

11 months ago

Soligenix Reports Promising Accomplishments and Financial Insights for 2024 Year-End Soligenix, Inc. shares its latest achievements and financial results for the year ending December 31, 2024, demonstrating significant progress in biopharmaceutical development.

Soligenix Reports Promising Accomplishments and Financial Insights for 2024 Year-End #United_States #Princeton #Soligenix #CTCL #HyBryte

Thiard News@F4F

@newsen.bsky.social

1 year ago

Soligenix to Showcase Innovations at BIO CEO & Investor Conference in New York Soligenix, a late-stage biopharmaceutical company, is set to present at the upcoming BIO CEO & Investor Conference in New York, highlighting its advancements in rare disease treatments.

Soligenix to Showcase Innovations at BIO CEO & Investor Conference in New York #United_States #New_York #biopharmaceuticals #Soligenix #HyBryte

Thiard News@F4F

@newsen.bsky.social

1 year ago

Soligenix to Showcase Innovations at Key Investor Conferences in 2025 Discover Soligenix's upcoming presentations at major investor conferences, showcasing groundbreaking therapies for rare diseases and public health.

Soligenix to Showcase Innovations at Key Investor Conferences in 2025 #United_States #Princeton #Soligenix #HyBryte #SNGX

Thiard News@F4F

@newsen.bsky.social

1 year ago

Exciting Progress in Treatment of Early-Stage Cutaneous T-Cell Lymphoma with HyBryte™ Soligenix, Inc. shares promising interim results from a study on HyBryte™, demonstrating positive outcomes in treating early-stage cutaneous T-cell lymphoma with a safety profile that stands out.

Exciting Progress in Treatment of Early-Stage Cutaneous T-Cell Lymphoma with HyBryte™ #None #Soligenix #CTCL #HyBryte